explore -WSS

explore

author：hotspot 2025-09-11 06:21:25 - browse：89

Home health and hospice chain Amedisys has chosen a new corporate owner.

Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： FDA official pushes for dedicated emerging pathogens team

WSS

White House touts steps to stem shortages of cancer treatments

What to know about Saharan dust affecting the US and how it can affect health

What to make of Biden’s latest efforts on cancer research

HIPAA doesn't protect reproductive records from prosecutors

As Taiwan prepares for anti

What to know about Saharan dust affecting the US and how it can affect health

leisure time

explore

Wikipedia

Jerome Adams on the need for new antivirals for Covid

Food makers tried to stack nutrition panel with preferred experts

Walensky prepares to leave CDC — and Congress — behind

White House touts steps to stem shortages of cancer treatments

Guidelines to prevent youth baseball injuries need more muscle

As Taiwan prepares for anti

Sports medicine is finally prioritizing gender equality

WATCH: Why do bright lights make us see spots?

Heart attack and stroke risk calculators need revising

How medical schools plan to diversify without affirmative action

Wikipedia

How artificial intelligence is being used to detect, treat cancer

Acelyrin, a rare IPO success, stumbles in its first big test

Court strikes down limits on filming of police in Arizona

FDA official pushes for dedicated emerging pathogens team

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Popular nasal decongestant doesn't actually relieve congestion

focus

focus

knowledge

knowledge